Hematology Drugs Market: By Drug Class, By Route of Administration,  By Drug Type, and Geography

download arrow download arrow Download Free Sample
settings arrow settings arrow email us

Hematology Drugs Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Class (Asparaginase-Specific Enzyme, Anthracycline Antibiotic, Antimetabolites, Enediyne Antitumor Antibiotics, Hypomethylating Agents, Antithrombotic Agents, Tyrosine Kinase Inhibitors), By Route of Administration (Oral, Parenteral),  By Drug Type (Small Molecules, Biologicals), and Region

checked icon arrow_drop_down
checked icon Single User License $4400 $3520
checked icon Multiple User License $6600 $5280
checked icon Corporate User License $8900 $7120

1. Executive Summary
2. Global Hematology Drugs Market Introduction
2.1. Global Hematology Drugs Market – Taxonomy
2.2. Global Hematology Drugs Market –Definitions
2.2.1. By Drug Class
2.2.2. By Route of Administration
2.2.3. By Drug Type
2.2.4. By Region
3. Global Hematology Drugs Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Hematology Drugs Market Dynamic Factors - Impact Analysis
3.6. Global Hematology Drugs Market – Competition Landscape
4. Global Hematology Drugs Market Analysis,2017-2021 and Forecast, 2022-2028
4.1. Market Analysis,2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Hematology Drugs Market, By Drug Class, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn)
5.1. Asparaginase-Specific Enzyme
5.1.1.  Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Anthracycline Antibiotic
5.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Antimetabolites
5.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Enediyne Antitumor Antibiotics
5.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Hypomethylating Agents
5.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Antithrombotic Agents
5.6.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
5.7. Tyrosine Kinase Inhibitors
5.7.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn)
5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.7.3. Market Opportunity Analysis
6. Global Hematology Drugs Market Forecast, By Route of Administration, 2017-2021 and Forecast, 2021 – 2027 (Revenue, US$ Mn)
6.1. Oral
6.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Parenteral
6.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
7. Global Hematology Drugs Market, By Drug Type, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn)
7.1. Small Molecules
7.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Biologicals
7.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
8. Global Hematology Drugs Market Forecast, By Region, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn)
8.1. North America
8.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Hematology Drugs Market - Opportunity Analysis Index, By Drug Class, Route of Administration, Drug Type, and Region, 2022-2028
9. North America Hematology Drugs Market Analysis,2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn)
9.1. By Drug Class Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Asparaginase-Specific Enzyme
9.1.2. Anthracycline Antibiotic
9.1.3. Antimetabolites
9.1.4. Enediyne Antitumor Antibiotics
9.1.5. Hypomethylating Agents
9.1.6. Antithrombotic Agents
9.1.7. Tyrosine Kinase Inhibitors
9.2. Route of Administration Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Oral
9.2.2. Parenteral
9.3. Drug Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%)
9.3.1. Small Molecules
9.3.2. Biologicals
9.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. USA
9.4.2. Canada
9.5. North America Hematology Drugs Market - Opportunity Analysis Index, By Drug Class, Route of Administration, Drug Type, and Country, 2022-2028
9.6. North America Hematology Drugs Market Dynamics – Trends
10. Europe Hematology Drugs Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn)
10.1. By Drug Class Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Asparaginase-Specific Enzyme
10.1.2. Anthracycline Antibiotic
10.1.3. Antimetabolites
10.1.4. Enediyne Antitumor Antibiotics
10.1.5. Hypomethylating Agents
10.1.6. Antithrombotic Agents
10.1.7. Tyrosine Kinase Inhibitors
10.2. Route of Administration Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Oral
10.2.2. Parenteral
10.3. Drug Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%)
10.3.1. Small Molecules
10.3.2. Biologicals
10.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
10.5. Europe Hematology Drugs Market - Opportunity Analysis Index, By Drug Class, Route of Administration, Drug Type, and Country, 2022-2028
10.6. Europe Hematology Drugs Market Dynamics – Trends
11. Asia-Pacific Hematology Drugs Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn)
11.1. By Drug Class Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Asparaginase-Specific Enzyme
11.1.2. Anthracycline Antibiotic
11.1.3. Antimetabolites
11.1.4. Enediyne Antitumor Antibiotics
11.1.5. Hypomethylating Agents
11.1.6. Antithrombotic Agents
11.1.7. Tyrosine Kinase Inhibitors
11.2. Route of Administration Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Oral
11.2.2. Parenteral
11.3. Drug Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%)
11.3.1. Small Molecules
11.3.2. Biologicals
11.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Hematology Drugs Market - Opportunity Analysis Index, By  Drug Class, Route of Administration, Drug Type, and Country, 2022-2028
11.6. Asia-Pacific Hematology Drugs Market Dynamics – Trends
12. Latin America Hematology Drugs Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn)
12.1. By Drug Class Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Asparaginase-Specific Enzyme
12.1.2. Anthracycline Antibiotic
12.1.3. Antimetabolites
12.1.4. Enediyne Antitumor Antibiotics
12.1.5. Hypomethylating Agents
12.1.6. Antithrombotic Agents
12.1.7. Tyrosine Kinase Inhibitors
12.2. Route of Administration Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Oral
12.2.2. Parenteral
12.3. Drug Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%)
12.3.1. Small Molecules
12.3.2. Biologicals
12.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Rest of Latin America
12.5. Latin America Hematology Drugs Market - Opportunity Analysis Index, By Drug Class, Route of Administration, Drug Type, and Country, 2022-2028
12.6. Latin America Hematology Drugs Market Dynamics – Trends
13. Middle East and Africa Hematology Drugs Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn)
13.1. By Drug Class Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Asparaginase-Specific Enzyme
13.1.2. Anthracycline Antibiotic
13.1.3. Antimetabolites
13.1.4. Enediyne Antitumor Antibiotics
13.1.5. Hypomethylating Agents
13.1.6. Antithrombotic Agents
13.1.7. Tyrosine Kinase Inhibitors
13.2. Route of Administration Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%)
13.2.1. Oral
13.2.2. Parenteral
13.3. Drug Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%)
13.3.1. Small Molecules
13.3.2. Biologicals
13.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Hematology Drugs Market - Opportunity Analysis Index, By Drug Class, Route of Administration, Drug Type, and Country, 2022-2028
13.6. MEA Hematology Drugs Market Dynamics – Trends
14. Competition Landscape 
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Route of Administration& Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Eli Lilly
14.2.2. Novartis
14.2.3. Celgene
14.2.4. Amgen Inc.
14.2.5. Sanofi S.A.
14.2.6. Pfizer Inc.
14.2.7. Jazz Pharmaceuticals
14.2.8. Bristol-Myers Squibb Company
14.2.9. Roche Holding AG
14.2.10. Baxalta
14.2.11. Angstrom Pharmaceuticals
15. Research Methodology
16. Key Assumptions and Acronyms

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Download Free Sample Report

I accept the Terms and Conditions,Disclaimers, GDPR Policy

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

Key Market Players

 
  • Eli Lilly
  • Novartis
  • Celgene
  • Amgen Inc.
  • Sanofi S.A.
  • Pfizer Inc.
  • Jazz Pharmaceuticals
  • Bristol-Myers Squibb Company
  • Roche Holding AG
  • Baxalta
  • Angstrom Pharmaceuticals

Related Industry Reports

Chronic Refractory Gout Pharmaceuticals Market

Familial Mediterranean Fever Pharmaceuticals Market

Australia Point of Care Diagnostics Market

Aseptic Sampling Market